Published in Diabetes on January 01, 2002
Aberrant Forkhead box O1 function is associated with impaired hepatic metabolism. Endocrinology (2006) 1.46
PPAR{alpha} mediates the hypolipidemic action of fibrates by antagonizing FoxO1. Am J Physiol Endocrinol Metab (2006) 1.18
Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic mice. J Lipid Res (2007) 0.98
Insulin expression in livers of diabetic mice mediated by hydrodynamics-based administration. World J Gastroenterol (2004) 0.90
Proteomic analysis of fructose-induced fatty liver in hamsters. Metabolism (2008) 0.89
Reversal of diabetes through gene therapy of diabetic rats by hepatic insulin expression via lentiviral transduction. Mol Ther (2012) 0.84
Delivery of a therapeutic protein by immune-privileged Sertoli cells. Cell Transplant (2010) 0.81
Glucose-regulated insulin production in the liver improves glycemic control in type 1 diabetic mice. Mol Metab (2014) 0.77
Correction of Diabetic Hyperglycemia and Amelioration of Metabolic Anomalies by Minicircle DNA Mediated Glucose-Dependent Hepatic Insulin Production. PLoS One (2013) 0.77
Hepatic insulin gene therapy prevents diabetic enteropathy in STZ-treated CD-1 mice. Mol Ther Methods Clin Dev (2015) 0.75
Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature (2003) 9.77
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res (2009) 3.18
Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology (2004) 3.00
Robust cellular reprogramming occurs spontaneously during liver regeneration. Genes Dev (2013) 2.96
HGF, SDF-1, and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver. J Clin Invest (2003) 2.89
Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology (2011) 2.66
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology (2013) 2.42
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32
Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology (2004) 2.29
FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J Clin Invest (2008) 2.16
Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice. Am J Physiol Endocrinol Metab (2003) 2.06
Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol (2006) 1.98
Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J Clin Invest (2004) 1.93
A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology (2009) 1.90
Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes (2002) 1.87
Elevated vascular endothelial growth factor production in islets improves islet graft vascularization. Diabetes (2004) 1.85
Retracted A genetically enhanced anaerobic bacterium for oncopathic therapy of pancreatic cancer. J Natl Cancer Inst (2008) 1.84
Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J Infect Dis (2008) 1.78
Retracted The oncopathic potency of Clostridium perfringens is independent of its alpha-toxin gene. Hum Gene Ther (2009) 1.70
Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl (2008) 1.68
Mechanism of sustained release of vascular endothelial growth factor in accelerating experimental diabetic healing. J Invest Dermatol (2009) 1.68
Beyond "cirrhosis": a proposal from the International Liver Pathology Study Group. Am J Clin Pathol (2012) 1.65
Pre-S2 deletion mutants of hepatitis B virus could have an important role in hepatocarcinogenesis in Asian children. Cancer Sci (2009) 1.61
Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res (2007) 1.53
Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery (2004) 1.51
Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res (2003) 1.50
Intrahepatic cholangiocarcinoma: new insights in pathology. Semin Liver Dis (2011) 1.46
Aberrant Forkhead box O1 function is associated with impaired hepatic metabolism. Endocrinology (2006) 1.46
Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors. Hepatology (2005) 1.44
Retracted Complete and persistent phenotypic correction of phenylketonuria in mice by site-specific genome integration of murine phenylalanine hydroxylase cDNA. Proc Natl Acad Sci U S A (2005) 1.43
Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice. Cancer Gene Ther (2005) 1.43
An ATF2-derived peptide sensitizes melanomas to apoptosis and inhibits their growth and metastasis. J Clin Invest (2002) 1.35
Retracted Metabolic basis of sexual dimorphism in PKU mice after genome-targeted PAH gene therapy. Mol Ther (2007) 1.25
Increased hepatic levels of the insulin receptor inhibitor, PC-1/NPP1, induce insulin resistance and glucose intolerance. Diabetes (2005) 1.24
Immunohistochemical evidence for hepatic progenitor cells in liver diseases. Liver (2002) 1.23
Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res (2004) 1.23
Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus. Mol Ther (2004) 1.21
Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo. Mol Ther (2007) 1.19
PPAR{alpha} mediates the hypolipidemic action of fibrates by antagonizing FoxO1. Am J Physiol Endocrinol Metab (2006) 1.18
Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV. Hepatology (2005) 1.17
Retracted Site-specific transgene integration in the human genome catalyzed by phiBT1 phage integrase. Hum Gene Ther (2008) 1.13
rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy. Hum Gene Ther (2008) 1.13
Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Mod Pathol (2010) 1.11
Oncolysis of hepatic metastasis of colorectal cancer by recombinant vesicular stomatitis virus in immune-competent mice. Mol Ther (2003) 1.09
Effects of glucose metabolism on the regulation of genes of fatty acid synthesis and triglyceride secretion in the liver. J Lipid Res (2007) 1.05
Myeloid-derived suppressor cells as a vehicle for tumor-specific oncolytic viral therapy. Cancer Res (2013) 1.04
Morphologic features of extrahepatic manifestations of hepatitis C virus infection. Clin Dev Immunol (2012) 1.04
T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis. J Autoimmun (2007) 1.03
Rejection of metastatic 4T1 breast cancer by attenuation of Treg cells in combination with immune stimulation. Mol Ther (2007) 0.99
Transcription releases protein VII from adenovirus chromatin. Virology (2007) 0.99
Interferons alpha, beta, gamma each inhibit hepatitis C virus replication at the level of internal ribosome entry site-mediated translation. Liver Int (2005) 0.99
Importance of specimen size in accurate needle liver biopsy evaluation of patients with chronic hepatitis C. Clin Gastroenterol Hepatol (2005) 0.97
Hepatic cavernous hemangioma: underrecognized associated histologic features. Liver Int (2006) 0.95
Inhibition of the IFN-beta response in hepatocellular carcinoma by alternative spliced isoform of IFN regulatory factor-3. Mol Ther (2008) 0.94
Functional genomic analysis of type II IL-1beta decoy receptor: potential for gene therapy in human arthritis and inflammation. J Immunol (2002) 0.93
Expression of human telomerase reverse transcriptase in regenerative and precancerous lesions of cirrhotic livers. Liver (2002) 0.92
Fusogenic vesicular stomatitis virus for the treatment of head and neck squamous carcinomas. Otolaryngol Head Neck Surg (2007) 0.92
Cholangiolocellular carcinoma: an innocent-looking malignant liver tumor mimicking ductular reaction. Semin Liver Dis (2011) 0.91
Destruction of canals of Hering in primary biliary cirrhosis. Hum Pathol (2002) 0.91
Treatment of multi-focal colorectal carcinoma metastatic to the liver of immune-competent and syngeneic rats by hepatic artery infusion of oncolytic vesicular stomatitis virus. Int J Cancer (2005) 0.90
Plasma cell hepatitis in hepatitis C virus patients post-liver transplantation: case-control study showing poor outcome and predictive features in the liver explant. Liver Transpl (2009) 0.90
Validation of preclinical multiparametric imaging for prediction of necrosis in hepatocellular carcinoma after embolization. J Hepatol (2011) 0.89
A versatile and tunable coating strategy allows control of nanocrystal delivery to cell types in the liver. Bioconjug Chem (2011) 0.88
Geographic characterization of hepatitis virus infections, genotyping of hepatitis B virus, and p53 mutation in hepatocellular carcinoma analyzed by in situ detection of viral genomes from carcinoma tissues: comparison among six different countries. Jpn J Infect Dis (2003) 0.88
Fulminant hepatic failure attributed to ackee fruit ingestion in a patient with sickle cell trait. Case Rep Transplant (2012) 0.87
Cholangiolocellular carcinoma in a pediatric patient with small duct sclerosing cholangitis: a case report. Semin Liver Dis (2013) 0.87
Hepatocellular carcinoma associated with an atypical presentation of Wilson's disease. Semin Liver Dis (2007) 0.87
Hepatocellular carcinoma arising in a pigmented telangiectatic adenoma with nuclear β-catenin and glutamine synthetase positivity: case report and review of the literature. Am J Surg Pathol (2011) 0.87
Drug-induced steatohepatitis leading to cirrhosis: long-term toxicity of amiodarone use. Semin Liver Dis (2009) 0.86
Hepatocellular carcinoma and congenital absence of the portal vein in a child receiving growth hormone therapy for turner syndrome. Semin Liver Dis (2007) 0.86
Clinical value and limitations of [11C]-methionine PET for detection and localization of suspected parathyroid adenomas. Mol Imaging Biol (2009) 0.86
Focal Nodular Hyperplasia and Hepatocellular Adenoma around the World Viewed through the Scope of the Immunopathological Classification. Int J Hepatol (2013) 0.86
Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing. Hepatology (2012) 0.85
Acute and chronic hepatitis. Semin Diagn Pathol (2007) 0.85
Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma. Laryngoscope (2008) 0.84
Oncolytic vesicular stomatitis virus administered by isolated limb perfusion suppresses osteosarcoma growth. J Orthop Res (2010) 0.84
Methotrexate therapy for primary biliary cirrhosis. Am J Gastroenterol (2003) 0.84
Primary hepatic signet ring cell neuroendocrine tumor: a case report with literature review. Semin Liver Dis (2010) 0.84
IFN-gamma sensitization of prostate cancer cells to Fas-mediated death: a gene therapy approach. Mol Ther (2003) 0.84
gC1qR expression in normal and pathologic human tissues: differential expression in tissues of epithelial and mesenchymal origin. J Histochem Cytochem (2012) 0.84
Histopathologic manifestations of drug-induced hepatotoxicity. Clin Liver Dis (2013) 0.83
A functional recombinant human 4-1BB ligand for immune costimulatory therapy of cancer. J Immunother (2011) 0.82
Cell cycle progression or translation control is not essential for vesicular stomatitis virus oncolysis of hepatocellular carcinoma. PLoS One (2010) 0.82
Jaundice accompanied by giant cell hepatitis and eosinophilia in childhood. Semin Liver Dis (2004) 0.82
Results of retransplantation for recurrent hepatitis C. Hepatology (2003) 0.82
Epstein-Barr virus and human hepatocellular carcinoma. Cancer Lett (2003) 0.82